Startups
A biotech company on a mission to crack the code on brain health. Through our breakthrough discovery tools, we aim to empower people with personalized biometrics to better navigate quality brain aging. Stay tuned for more information on upcoming services.
Overview
Location
United States
Employees
11-50
Founded date
2007
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 9, 2026 | Amprion Receives Financing From Decathlon Capital Partners | Amprion, Inc., a San Diego, CA-based company advancing diagnosis of neurodegenerative disorders through seed-amplification testing, received a multi-million-dollar financing from Decathlon Capital Partners. The exact amount of the deal was ... |
| Sep 15, 2022 | Amprion Exhibits at MDS International Congress of Parkinson's Disease and Movement Disorders in Madrid and Presents Scientific Insights On SYNTap® Test at Prion2022 | Amprion, a leader in diagnostics for neurodegenerative diseases, invites researchers and practitioners attending the MDS International Congress in Madrid to visit Amprion at booth #212 and discuss how the SYNTap® Biomarker Test addresses th... |
| Sep 15, 2022 | Amprion Exhibits at MDS International Congress of Parkinson’s Disease and Movement Disorders in Madrid and Presents Scientific Insights On SYNTap® Test at Prion2022 | “The SYNTap Test fills the void for a highly sensitive and specific clinical diagnostics tool” -Amprion Chief Scientific Officer Claudio Soto, Ph.D. SAN FRANCISCO (PRWEB) September 15, 2022 Amprion, a leader in diagnostics for neurodegenera... |
| May 10, 2022 | Amprion Awarded NIH Grant For Analytical Validation of SYNTap® Biomarker Test For Neurological Disease | Amprion R&D Assoc Director, Luis Concha, runs experiments Amprion announces the National Institute of Neurological Disorders and Stroke (NINDS) has awarded an additional research grant of approximately $730,000 for continued validation ... |
| Apr 6, 2022 | SYNTap Biomarker Test helps doctors distinguish Parkinson’s Disease from Parkinsonism in early stages | “We are excited about the promise of molecular testing. Knowing the biomarker gives us a target for effective treatment and drug innovation. By directing proper medicine to the target biomarker, we can develop successful treatments for Park... |
| Mar 31, 2022 | Amprion Announces Commercial Rollout of SYNTap Test at the AAN Annual Meeting and Formation of Clinical Advisory Board | The SYNTap Biomarker Test helps doctors diagnose Parkinson’s, Lewy Body Dementia, and Lewy Body Variant of Alzheimer’s We invite AAN Annual Meeting attendees to visit Amprion’s booth #1074 and meet our CEO/Co-Founder and clinical director. ... |
| Jan 19, 2022 | New Insights On Alzheimer's And What It Means For Personalized Medicine | Amprion-New Insights on Alzheimer's "for the first time, the SYNTap Test enables physicians to distinguish Alzheimer's with Lewy Bodies early—during patients' lifetimes. The advent of molecular diagnostics will accelerate innovations i... |
| Oct 6, 2021 | Amprion announces SYNTap™ Biomarker Test for early detection of Parkinson's Disease (PD), Lewy Body Dementia (LBD), and Alzheimer's Disease (AD) | Amprion R&D Assoc Director, Luis Concha, runs experiments "Our technology detects the prion biomarkers in CSF samples years before patients show symptoms. Early diagnosis is crucial because it enables physicians to steer their pati... |
| AMPRION | “SYNTap Test helps doctors diagnose LBD and Parkinson's accurately. Our breakthrough test detects misfolded Synuclein, a biomarker related to these diseases.” |
Reviews 0
FAQ about Amprion
When was Amprion founded?
Amprion was founded in 2007.
What has the press written about Amprion?
Parsers VC has collected 10 articles mentioning Amprion, among them “Amprion Receives Financing From Decathlon Capital Partners” (Jul 9, 2026) and “Amprion Exhibits at MDS International Congress of Parkinson's Disease and Movement Disorders in Madrid and Presents Scientific Insights On SYNTap® Test at Pr...” (Sep 15, 2022).
Is Amprion still active?
Yes, Amprion is active; its latest activity on Parsers VC dates from Jul 10, 2026.